Anti-cancer effect of nano-encapsulated boswellic acids, curcumin and naringenin against HepG-2 cell line
- Open Access
- 01-12-2023
- Hepatocellular Carcinoma
- Research
- Authors
- Sally Elnawasany
- Yusuf A. Haggag
- Shahinaz M. Shalaby
- Nema A. Soliman
- Amira A. EL Saadany
- Marwa A. A. Ibrahim
- Farid Badria
- Published in
- BMC Complementary Medicine and Therapies | Issue 1/2023
Abstract
Background
liver cancer is one of the most common cancers in the world. So far, there is no gold standard treatment for hepatocellular carcinoma. We conducted this in vitro study to assess the effect of three natural products: Boswellic acids, curcumin and naringin versus corresponding nanoparticles (NPs) on Hep G2 cells proliferation.
Methods
Boswellic acid, curcumin, naringin-loaded NPs were prepared using nanoprecipitation method. Human liver (HepG2) cell line was cultured in Dulbecco’s modified Eagle’s medium (DMEM). The cell growth inhibition and cytotoxicity were evaluated by MTT assay.
Results
Boswellic acid, curcumin, naringin were able to inhibit HepG2 cells proliferation. IC50 at 24 h, 48 h showed significant lower values in NPs versus Free herbs. IC50 values of free Boswellic acids and NPs at 24 h were (24.60 ± 1.89 and 7.78 ± 0.54, P < 0.001), at 48 h were (22.45 ± 1.13 and 5.58 ± 0.27, P < 0.001) respectively. IC50 values of free curcumin and NPs at 24 h were (5.89 ± 0.8 and 3.46 ± 0.23, P < 0.05), at 48 h were (5.57 ± 0.94 and 2.51 ± 0.11, P < 0.05), respectively. For free and naringenin NPs, IC50 values at 24 h were (14.57 ± 1.78 and 7.25 ± 0.17, P < 0.01), at 48 h were (11.37 ± 1.45 and 5.21 ± 0.18, P < 0.01) respectively.
Conclusion
Boswellic acid, curcumin, naringin and their nanoprecipitation prepared nanoparticles suppressed Hep G2 cells proliferation.
Advertisement
- Title
- Anti-cancer effect of nano-encapsulated boswellic acids, curcumin and naringenin against HepG-2 cell line
- Authors
-
Sally Elnawasany
Yusuf A. Haggag
Shahinaz M. Shalaby
Nema A. Soliman
Amira A. EL Saadany
Marwa A. A. Ibrahim
Farid Badria
- Publication date
- 01-12-2023
- Publisher
- BioMed Central
- Published in
-
BMC Complementary Medicine and Therapies / Issue 1/2023
Electronic ISSN: 2662-7671 - DOI
- https://doi.org/10.1186/s12906-023-04096-4
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.